期刊
DRUG DISCOVERIES AND THERAPEUTICS
卷 14, 期 5, 页码 259-261出版社
INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT
DOI: 10.5582/ddt.2020.03095
关键词
COVID-19; post-COVID syndrome; pulmonary fibrosis; mast cell
资金
- MEXT KAKENHI Grant [16K08484]
- Salt Science Research Foundation [2028]
- Tojuro Iijima Foundation for Food Science and Technology [2019-12]
- National Institute for Physiological Sciences [19-305]
- Grants-in-Aid for Scientific Research [16K08484] Funding Source: KAKEN
Regardless of the severity of coronavirus disease 2019 (COVID-19), a high proportion of patients struggle with persistent respiratory or systemic symptoms after recovery. This is called post-COVID syndrome, for which pulmonary fibrosis is one of the pathogenesis. Besides T-lymphocytes and macrophages, mast cells also contribute to the development of cytokine storm and thus stimulate the activity of fibroblasts. Additionally, by the exocytotic release of fibroblast-activating factors, mast cells directly facilitate the progression of pulmonary fibrosis. In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed their potency as highly effective mast cell stabilizers. Given such pharmacological properties of these commonly used drugs, they may be useful in the treatment of post-COVID-19 pulmonary fibrosis and in relieving the symptoms of post-COVID syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据